Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1166

1.

Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability.

Spyridopoulos I, Luedemann C, Chen D, Kearney M, Chen D, Murohara T, Principe N, Isner JM, Losordo DW.

Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):901-6.

2.

Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties.

Chang YS, Munn LL, Hillsley MV, Dull RO, Yuan J, Lakshminarayanan S, Gardner TW, Jain RK, Tarbell JM.

Microvasc Res. 2000 Mar;59(2):265-77.

PMID:
10684732
3.

Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.

Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL.

Diabetes. 1997 Sep;46(9):1473-80.

PMID:
9287049
4.

Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro.

van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW.

Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):211-7.

5.

Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.

Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H.

Cancer Res. 1999 Sep 1;59(17):4413-8.

6.

Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin.

Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM.

Circulation. 1998 Jan 6-13;97(1):99-107.

7.

Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability.

Eriksson A, Cao R, Roy J, Tritsaris K, Wahlestedt C, Dissing S, Thyberg J, Cao Y.

Circulation. 2003 Mar 25;107(11):1532-8.

9.

Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide.

Wang J, Morita I, Onodera M, Murota SI.

J Cell Physiol. 2002 Feb;190(2):238-50.

PMID:
11807828
10.
11.
13.

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.

Mol Cancer Res. 2002 Nov;1(1):2-11.

14.

Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.

J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85.

15.

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N.

J Biol Chem. 2001 Feb 2;276(5):3222-30.

18.

Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability.

Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ.

Am J Physiol. 1999 Feb;276(2 Pt 2):H535-42.

19.

Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.

Jia H, Jezequel S, Löhr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I.

Biochem Biophys Res Commun. 2001 Apr 27;283(1):164-73.

PMID:
11322784
20.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
Items per page

Supplemental Content

Support Center